Know Cancer

or
forgot password

"Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Terminal Patients With Primary Lung Cancer or Lung metastases-a Pilot Study


Phase 4
18 Years
N/A
Not Enrolling
Both
Dyspnea, Lung Neoplasms

Thank you

Trial Information

"Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Terminal Patients With Primary Lung Cancer or Lung metastases-a Pilot Study


Breathlessness or dyspnea in terminal cancer patients with lung cancer is common and opioids
such as morphine is the mainstay of symptomatic treatment. Subcutaneous administration of
morphine provides fast symptomatic relief, but it has been the impression in our institution
that "red morphine drops" applied orally may have equal or better efficacy and faster onset
time.

Comparison: Patients with lung cancer or lung metastases with moderate to severe dyspnea at
rest are treated with either orally applied "red morphine drops" or an equivalent amount of
morphine applied subcutaneously.


Inclusion Criteria:



- Primary lung cancer or lung metastases and

- Moderate to severe dyspnea at rest (VAS equal to or more than 30)

Exclusion Criteria:

- Causal treatment of dyspnea possible and indicated

- Not receiving opioids on a regular basis

- Methadone treatment

- Intolerance to morphine

- Without understanding of patient information

- Depressed consciousness

- Oxygen treatment, if changed with-in 20 min before start

- Short-acting opioids with-in 4 h before start

- Inhalation therapy for bronchodilation with-in 20 min before start

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Outcome Measure:

Dyspnea on a VAS scale

Outcome Time Frame:

1 hour

Safety Issue:

No

Principal Investigator

Torben Krantz, Physician

Investigator Role:

Principal Investigator

Investigator Affiliation:

Sankt Lukas Hospice

Authority:

Denmark: Danish Medicines Agency

Study ID:

2005-060-version1a

NCT ID:

NCT00338481

Start Date:

April 2006

Completion Date:

February 2011

Related Keywords:

  • Dyspnea
  • Lung Neoplasms
  • Neoplasms
  • Dyspnea
  • Lung Neoplasms

Name

Location